Who is sponsoring NCT03867123?

NCT03867123 is sponsored by Laminar Pharmaceuticals.

What condition does NCT03867123 study?

NCT03867123 studies Glioblastoma (GBM).

What drugs are being tested in NCT03867123?

Interventions: LAM561, RT, TMZ.

What is the status of NCT03867123?

NCT03867123 is currently COMPLETED.

Last reviewed 2023-02-21 · How we verify

A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients

NCT03867123 PHASE1 COMPLETED

The purpose of this study is to determine the safety and tolerability of LAM561 added to first-line treatment for subjects with newly diagnosed glioblastoma (GBM), and to determine the highest safe dose of LAM561 administered orally when added to the concurrent phase of treatment with temozolomide (TMZ) and radiation therapy (RT) or when added to the maintenance phase of treatment with TMZ (once TMZ 200 g/m2/day is started).

Details

Lead sponsor	Laminar Pharmaceuticals
Phase	PHASE1
Status	COMPLETED
Enrolment	18
Start date	Tue Dec 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jul 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Glioblastoma (GBM)

Interventions

LAM561
RT
TMZ

Countries

Spain